Guarana (Paullinia cupana) presents a safe and effective anti-fatigue profile in patients with chronic kidney disease: A randomized, double-blind, three-arm, controlled clinical trial

Publication date: December 2018Source: Journal of Functional Foods, Volume 51Author(s): Ieda Maria Pedroso Dorneles, Mateus Batista F.s, Paula Caitano Fontela, Matias Nunes Frizzo, Eliane Roseli WinkelmannAbstractThe effects of guarana (Paullinia cupana) supplementation in capsules, for 30 days, were evaluated for the following dosages: placebo, 200 mg/day, and 400 mg/day. Clinical symptomatology, hematological, biochemical, and renal function parameters were evaluated in chronic kidney disease patients undergoing hemodialytic treatment. Most patients in the groups of 200 mg/day and 400 mg/day of guarana reported increased mood/energy, decreased fatigue, and increased appetite. The rate of patients reporting increased headache, insomnia, gastric discomfort, and nausea/vomiting was higher in the 400 mg/day group, while most patients in the placebo group and 200 mg/day of guarana group did not report any changes. The 200 mg/day and 400 mg/day groups had higher hemoglobin and hematocrit values after 30 days of supplementation when compared to the placebo group. Additionally, a reduction in hematological parameters and increase in glucose were seen in the placebo group. Guarana, especially at a dosage of 200 mg/day, is safe and effective in improving clinical symptoms and maintaining hemoglobin and hematocrit values.Graphical abstract
Source: Journal of Functional Foods - Category: Nutrition Source Type: research